To investigate if these master regulators could act as a core signature for clinically aggressive cancers, we explored an OCT4/SOX2/NANOG (OSN) expression signature in a large cohort of clinical cancers (n = 884), comprising of prostate (n = 275), bladder (n = 292) and renal cancers (n = 317) (Fig. 1). Here, NANOG is linked to renal carcinoma.